Zevra Therapeutics Inc
Research Zevra Therapeutics Inc (ZVRA) on Bullrun: market cap USD 675.90M, P/E 12.3. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerZVRA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 675.90M
- P/E12.3
- Financial periodQ2 2026
- RevenueUSD 39.66M
- Net incomeUSD 8.75M
- Free cash flowUSD 16.82M
- Gross margin96.2%
Valuation Snapshot
latest market cap is USD 675.90M; P/E is 12.3.
Peer valuation comparison
Latest P/E is 12.29x versus a Healthcare sector median of 24.64x (50.1% below).
Latest P/E is 12.29x versus a United States median of 23.85x (48.5% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 106.47M | USD 83.23M | -USD 2.43M | 84.5% | 1.35 | USD 62.41M | USD 61.93M | USD 154.66M |
| FY2024 | USD 23.61M | -USD 105.51M | -USD 69.67M | 68.6% | -2.28 | USD 33.79M | USD 59.50M | USD 39.67M |
| FY2023 | USD 27.46M | -USD 46.05M | -USD 33.83M | 89.3% | -1.3 | USD 43.05M | USD 5.07M | USD 61.86M |
| FY2022 | USD 10.16M | -USD 26.77M | -USD 18.81M | 97.8% | -1.2 | USD 65.47M | USD 14.12M | USD 75.12M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 675.90M | 12.3 | n/a | n/a |
| 2025 | 2025-12-31 | USD 509.42M | 6.0 | n/a | n/a |
| 2024 | 2024-12-31 | USD 447.61M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 256.66M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 158.38M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 304.90M | n/a | n/a | n/a |
About Zevra Therapeutics Inc
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy.
ETFs that hold Zevra Therapeutics Inc
Zevra Therapeutics Inc is one of the ten largest holdings of one ETF that investors in Europe can buy:
| ETF | Weight | TER |
|---|---|---|
| L&G Pharma Breakthrough UCITS ETF | 3.00% | 0.49% |
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Zevra Therapeutics Inc's market cap?
Zevra Therapeutics Inc's market capitalization is USD 675.90M.
What is Zevra Therapeutics Inc's P/E ratio?
Zevra Therapeutics Inc's price-to-earnings (P/E) ratio is 12.3.
What does Zevra Therapeutics Inc do?
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy.